Hydrogen Peroxide

Hydrogen Peroxide

SCHEMBL3706944

NC1=CC=C(c2ccc(N)cc2)CC1(N)N.OO

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41543 0.96 CYP3A4 (0.39) CYP3A4TDP1ALDH1A1TP53TAAR1
Hydrochloric Acid SCHEMBL71899 0.94 CYP3A4 (0.37) CYP3A4TDP1ALDH1A1TP53TAAR1
Water SCHEMBL28537381 0.94 CYP3A4 (0.37) CYP3A4TDP1ALDH1A1TP53TAAR1
Hydrochloric Acid SCHEMBL3286109 0.94 CYP3A4 (0.37) CYP3A4TDP1ALDH1A1TP53TAAR1
Hydrochloric Acid SCHEMBL28977209 0.93 CYP3A4 (0.36) CYP3A4TDP1ALDH1A1TP53TAAR1
Hydrochloric Acid SCHEMBL21357686 0.93 CYP3A4 (0.36) CYP3A4TDP1ALDH1A1TP53TAAR1
Hydrochloric Acid SCHEMBL557242 0.93 CYP3A4 (0.36) CYP3A4TDP1ALDH1A1TP53TAAR1
Carbon Tetrachloride SCHEMBL29029110 0.89 ALDH1A1 (0.33) CYP3A4TDP1ALDH1A1TP53
SCHEMBL5803242 0.85 CYP3A4 (0.49) CYP3A4HSD17B10
SCHEMBL22289155 0.81 GRM8 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107849533-A Use of mesenchymal stem cells for the treatment of osteoarthritis 洪士杰 2018-03-27 CN disclosed
US-9775930-B2 Composition for modifying myocardial infarction expansion ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2017-10-03 US disclosed
US-20170258961-A9 COMPOSITION FOR MODIFYING MYOCARDIAL INFARCTION EXPANSION ABBOTT CARDIOVASCULAR SYSTEMS INC (US) 2017-09-14 US disclosed
EP-2452699-B1 Scaffolding for modifying myocardial infarction expansion ABBOTT CARDIOVASCULAR SYSTEMS (US) 2016-04-20 EP disclosed
US-20150209473-A1 METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION ABBOTT CARDIOVASCULAR SYSTEMS (US) 2015-07-30 US disclosed
US-9005672-B2 Methods of modifying myocardial infarction expansion ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2015-04-14 US disclosed
EP-2109469-B1 METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION ABBOTT CARDIOVASCULAR SYSTEMS (US) 2014-06-04 EP disclosed
EP-2452699-A1 Methods of modifying myocardial infarction expansion Abbott Cardiovascular Systems Inc. (US) 2012-05-16 EP disclosed
EP-2109469-A2 METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION Abbott Cardiovascular Systems Inc. (US) 2009-10-21 EP disclosed
US-20090022817-A1 METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION MICHAL EUGENE T 2009-01-22 US disclosed
WO-2008089452-A2 METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2008-07-24 WO disclosed
US-5807556-A ADMINISTERING FIBROBLAST GROWTH FACTOR AND ELECTRICAL STIMULATION THOMAS JEFFERSON UNIVERSITY (US) 1998-09-15 US disclosed
EP-0385415-B1 Process for producing NADH oxidase MITSUBISHI PETROCHEMICAL CO (JP) 1995-06-07 EP disclosed
US-5416012-A Process for producing NADH oxidase MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1995-05-16 US disclosed
US-5336608-A Culturing a genetically engineered alkalophilic, facultative anaerobic bacterium MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1994-08-09 US disclosed
EP-0385415-A1 Process for producing NADH oxidase MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1990-09-05 EP disclosed